GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Cash From Discontinued Investing Activities

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Clarus Therapeutics Holdings's cash from discontinued investing activities for the three months ended in Jun. 2022 was $0.00 Mil. It means Clarus Therapeutics Holdings received $0.00 Mil from discontinued investing activities. Clarus Therapeutics Holdings's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.


Clarus Therapeutics Holdings Cash From Discontinued Investing Activities Historical Data

The historical data trend for Clarus Therapeutics Holdings's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Cash From Discontinued Investing Activities Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
Cash From Discontinued Investing Activities
- -

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash From Discontinued Investing Activities Get a 7-Day Free Trial - - - - -

Clarus Therapeutics Holdings Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarus Therapeutics Holdings Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus